Alnylam Pharmaceuticals (ALNY) EBIT (2009 - 2026)

Alnylam Pharmaceuticals has reported EBIT for 18 years, with the latest figure at $268.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 1386.07% year-over-year to $268.6 million; the trailing twelve-month figure through Mar 2026 stood at $752.1 million (up 751.92% YoY), and the FY2025 full-year result was $501.6 million, up 383.56% from the prior year.
• EBIT for Q1 2026 stood at $268.6 million, up from $131.7 million in the prior quarter.
• The five-year high for EBIT was $368.0 million in Q3 2025, with the low at -$258.0 million in Q3 2022.
• Historically, EBIT has averaged -$27.9 million across 5 years, with a median of -$76.9 million in 2024.
• Annual changes were most pronounced in 2024 — EBIT sank 135.96% — and 2026, when it soared 1386.07%.
• Alnylam Pharmaceuticals' EBIT stood at -$188.6 million in 2022, then jumped by 38.28% to -$116.4 million in 2023, then climbed by 9.66% to -$105.2 million in 2024, then soared by 225.26% to $131.7 million in 2025, then surged by 103.95% to $268.6 million in 2026.
• The last three EBIT figures came in at $268.6 million (Q1 2026), $131.7 million (Q4 2025), and $368.0 million (Q3 2025), per Business Quant data.